Showing results (1561-1570 of 1,714) with videos related to

Sort By:
Pageof 172
ACS Synthetic Biology|December 20, 2014
Design and characterization of a modular membrane protein anchor to functionalize the moss Physcomitrella patens with extracellular catalytic and/or binding activitiesVolker Morath, Dong-Jiunn Jeffery Truong, Florian Albrecht, et al.
Plant Disease|January 26, 2019
Strain-Specific Resistance to Potato virus Y (PVY) in Potato and Its Effect on the Relative Abundance of PVY Strains in Commercial Potato FieldsCassandra N Funke, Olga V Nikolaeva, Kelsie J Green, et al.
BMC Nephrology|February 6, 2021
Effect of balanced crystalloids versus saline on urinary biomarkers of acute kidney injury in critically ill adultsBlake E Funke, Karen E Jackson, Wesley H Self, et al.
Atherosclerosis|April 9, 2013
Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular diseaseJohannes Tobias Neumann, Stergios Tzikas, Anne Funke-Kaiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformationTorsten Trowe, Sotiria Boukouvala, Keith Calkins, et al.
European Heart Journal|January 14, 2017
Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genesRoddy Walsh, Rachel Buchan, Alicja Wilk, et al.
BMJ Open Respiratory Research|April 23, 2022
Frailty assessment for COVID-19 follow-up: a prospective cohort studyIlena Müller, Marco Mancinetti, Anja Renner, et al.
Trials|July 9, 2024
A web-based video messaging intervention for suicide prevention in men: study protocol for a five-armed randomised controlled trialJin Han, Aimy Slade, Hiroko Fujimoto, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 1, 2018
Provision of assistive technology devices among people with ALS in Germany: a platform-case management approachAndreas Funke, Susanne Spittel, Torsten Grehl, et al.
The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Pageof 172